SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

  • Org Study ID: FT500-101
  • Secondary ID:
  • NCT ID: NCT03841110
  • NCT Alias:
  • Sponsor: Fate Therapeutics - Industry
  • Source: Fate Therapeutics

Brief Summary

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.

Overal Status Start Date Phase Study Type
Recruiting February 15, 2019 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.

Primary Outcome 1 - Time Frame: Day 29


  • Advanced Solid Tumors
  • Lymphoma
  • Gastric Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • EGFR Positive Solid Tumor
  • HER2-positive Breast Cancer
  • Hepatocellular Carcinoma
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Pancreas Cancer
  • Melanoma
  • Urothelial Carcinoma
  • Cervical Cancer
  • Microsatellite Instability
  • Merkel Cell Carcinoma


Inclusion Criteria:

1. Diagnosis of the following, as per Regimen Cohort:

1A. Regimen A: FT500 Monotherapy (Dose Escalation and Expansion): An advanced solid tumor
malignancy, including lymphoma, in a subject who has failed or refused available
FDA-approved therapies and is now a candidate for salvage therapy.

1B. Regimen B: FT500 + ICI (Dose Escalation): An advanced solid tumor malignancy, including
lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab,
pembrolizumab or atezolizumab), in a subject who has also failed or refused other available
approved therapies and is now a candidate for salvage therapy.

1C. Regimen B: FT500 + ICI (Dose Expansion): An advanced solid tumor malignancy, including
lymphomas, in a subject who is currently receiving nivolumab, pembrolizumab or atezolizumab
per USPI, with disease progression on the ICI.

2. Provision of signed and dated ICF.

3. Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start
of lympho-conditioning and within 28 days prior to Day 1.

4. Stated willingness to comply with study procedures and duration. 5. Provision of signed
and dated ICF to agree to participate, at time of withdrawal or completion of this study,
in Fate Therapeutics' long-term, non-interventional, observation study, FT-003.

Exclusion Criteria:

All Subjects:

1. Females of reproductive potential who are pregnant or lactating, and males or females
not willing to use a highly effective form of contraception from Screening through the
end of the study.

2. ECOG performance status ≥ 2.

3. Evidence of insufficient organ function as determined by any one of the following:

1. Neutrophils <1000/µL or platelets <75,000/µL.

2. Estimated creatinine clearance <50 mL/minute (Cockcroft-gault).

3. Total bilirubin >2 x upper limit normal (ULN) with the exception of subjects with
Gilbert's Syndrome or known liver metastases.

4. Aspartate aminotransferase (AST) >3 x ULN, or alanine aminotransferase (ALT) >3 x
ULN. For subjects with known liver metastases, AST or ALT >5 x ULN.

5. Oxygen saturation <90% on room air; pulmonary function tests (PFTs) required if
symptomatic or prior known impairment - subject will be excluded if diffusing
capacity of the lungs for carbon monoxide (DLCO) or forced expiratory volume 1
(FEV1) is <50% of predicted for height and age.

6. Left ventricular ejection fraction (LVEF) <40% (eg by echocardiogram (ECHO) or
multi-gated acquisition (MUGA) scan).

4. Receipt of any biological therapy, chemotherapy, or radiation (except palliative
radiation) within 2 weeks prior to Day 1. Subjects in Regimen B currently taking an
ICI must interrupt ICI dosing at least 2 weeks prior to Day 1.

5. CNS metastases that have not been treated; or treated CNS metastases that have not
been stable for at least 6 months.

6. Clinically significant cardiovascular disease, including stroke or myocardial
infarction within 6 months prior to first study medication; or the presence of
unstable angina or congestive heart failure of New York Heart Association grade 2 or

7. Currently receiving or likely to require systemic immunosuppressive therapy (eg,
prednisone >5 mg daily) for any reason from Day -7 to Day 29.

8. Uncontrolled infections.

9. Known allergy to the following FT500 components: Albumin (Human) or DMSO.

10. Presence of any medical or social issues that are likely to interfere with study
conduct, or may cause increased risk to subject.

Additional Exclusion Criteria for Regimen B: FT500 + ICI:

11. Subjects who experienced an ICI-related adverse reaction that resulted in
discontinuation of the ICI.

12. Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid
arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's
disease, ulcerative colitis), except for subjects with isolated vitiligo, atopic
dermatitis, controlled hypoadrenalism or hypopituitarism, and controlled thyroid

13. Subjects who have received an allograft organ transplant.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Wayne Chu, MD

Role: Study Director

Affiliation: Fate Therapeutics

Overall Contact

Name: Meenal Patel

Phone: 858-875-1800



Facility Status Contact
UCSD Moores Cancer Center
San Diego, California 92093
United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota 55455
United States
MD Anderson Cancer Center
Houston, Texas 77030
United States